key: cord-0686165-2digi8b7
authors: Oniszczuk, Julie; Pagot, Eléonore; Limal, Nicolas; Hue, Sophie; Audard, Vincent; Moktefi, Anissa; El Karoui, Khalil
title: Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2
date: 2021-07-30
journal: Kidney Int
DOI: 10.1016/j.kint.2021.07.018
sha: efcd3bde683de2427f37b6d96d9495d129718a8a
doc_id: 686165
cord_uid: 2digi8b7

nan

syndrome, or drug-induced HUS. Finally, the close temporal relationship (7d) between the first administration of BNT162b2 vaccine and the apparition of hypertensive symptoms emphasizes the potential role of immune response to SARS-CoV-2 mRNA vaccination as a trigger of SRC.

Whether other diseases associated with hemolytic uremic syndrome/thrombotic microangiopathy (such as thrombotic thrombocytopenic purpura, complement-mediated atypical HUS, chemotherapy-associated HUS, or organ transplant associated-HUS) could be triggered by mRNA vaccination remains to be demonstrated. 

Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique

Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB)

Centre de Référence Maladie Rare « Cytopénies auto-immunes »

De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?

AJKD Atlas of Renal Pathology: Systemic Sclerosis

Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis Rheumatol Hoboken NJ

COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study